SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry

这项小型企业创新研究(SBIR)第一阶段研究项目旨在开发一种重要的毒性生物标志物肌酸激酶的护理点分析，以筛选使用全血的不良药物反应(ADR)。该分析将利用包含量子点的生物发光共振能量转移(BRET)探针。这项拟议的技术可能会影响毒性测试，使医生能够在早期阶段测试潜在的ADR并采取纠正措施。由于超过50%的联邦医疗保险患者服用多种药物，发生不良反应的可能性很高，任何廉价和可靠的毒性测试都将对这些个人和整个社会有利。

This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.